Friday, February 23, 2024 |

Baltimore’s Haystack Oncology, TriSalus Life Sciences to develop liver cancer treatment

January 23, 2024

Baltimore-based Haystack Oncology, a Quest Diagnostics company and developer of personalized MRD technology, has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development of TriSalus’ SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist.

Article Source: The Daily Record

The Morning Rundown

We’re staying up to the minute on the issues shaping the future. Join us on the newsletter of choice for Maryland politicos and business leaders. It’s always free to join and never a hassle to leave. See you on the inside.